Similar articles

• Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes.

  Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Douketis JD, et al. Arch Intern Med. 2002 Jul 8;162(13):1465-71. doi: 10.1001/archinte.162.13.1465. Arch Intern Med. 2002. PMID: 12090882
• Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.

  Eikelboom JW, Quinlan DJ, Douketis JD. Eikelboom JW, et al. Lancet. 2001 Jul 7;358(9275):9-15. doi: 10.1016/S0140-6736(00)05249-1. Lancet. 2001. PMID: 11454370
• Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.

  Runner RP, Gottschalk MB, Staley CA, Pour AE, Roberson JR. Runner RP, et al. J Arthroplasty. 2019 Apr;34(4):729-734. doi: 10.1016/j.arth.2018.12.015. Epub 2018 Dec 22. J Arthroplasty. 2019. PMID: 30685257
• Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

  Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Stevenson M, et al. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Health Technol Assess. 2009. PMID: 19846028 Review.
• Clinical experience with ximelagatran in orthopaedic surgery.

  Eriksson B. Eriksson B. Drugs. 2004;64 Suppl 1:27-35. doi: 10.2165/00003495-200464001-00005. Drugs. 2004. PMID: 15586625 Review.